drug screening organoid cancer therapeutic
Strong first-pass evidence signal
The strongest current signal is drug screening evidence. The top-ranked source is Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. (2019). Manual verification is required before using this as a client-facing conclusion.
High confidence for a first-pass paid pilot brief
Executive Snapshot
ranked evidence rows
evidence categories
year coverage
source families
Key Findings
- Finding 1: drug screening evidence is represented by Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. (2019). Lung cancer organoids respond to drugs based on their genomic alterations: a BRCA2-mutant organoid to olaparib, an EGFR-mutant organoid to erlotinib, and an EGFR-mutant/MET-amplified organoid to crizotinib.
- Finding 2: drug screening evidence is represented by Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. (2017). PLC-derived organoids are amenable for biomarker identification and drug-screening testing and led to the identification of the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer.
- Finding 3: drug screening evidence is represented by Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. (2019). The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines.
Evidence Dashboard
Evidence Mix
Source Coverage
Year Timeline
Quality Signals
Rows with an extracted sentence that can be checked by a reviewer.
Rows with usable publication year metadata for timeline interpretation.
Public source diversity proxy based on link families in the ranked table.
Whether the map has multiple evidence types rather than one narrow cluster.
Top Evidence
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.
2019
Lung cancer organoids respond to drugs based on their genomic alterations: a BRCA2-mutant organoid to olaparib, an EGFR-mutant organoid to erlotinib, and an EGFR-mutant/MET-amplified organoid to crizotinib.
Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
2017
PLC-derived organoids are amenable for biomarker identification and drug-screening testing and led to the identification of the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer.
Application of Cancer Organoid Model for Drug Screening and Personalized Therapy.
2019
The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines.
Establishment of patient-derived cancer organoids for drug-screening applications.
2020
The protocol provided may serve as a reference to successfully establish organoids from other cancer types and perform drug screenings thereof.
Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids.
2024
The anticancer activities of drug candidates were further validated in the established patient-derived organoids-based xenograft (PDOX) system in vivo.
Ranked Evidence Table
| # | Evidence | Year | Paper | Rationale | Support sentence | Source |
|---|---|---|---|---|---|---|
| 1 | drug screening evidence | 2019 | Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. | Query term overlap: drug, screening, organoid, cancer, therapeutic; quality=2.51; cited_by=588; pmcid=PMC6728380 | Lung cancer organoids respond to drugs based on their genomic alterations: a BRCA2-mutant organoid to olaparib, an EGFR-mutant organoid to erlotinib, and an EGFR-mutant/MET-amplified organoid to crizotinib. | source |
| 2 | drug screening evidence | 2017 | Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. | Query term overlap: drug, screening, organoid, cancer, therapeutic; quality=2.50; cited_by=1078; pmcid=PMC5722201 | PLC-derived organoids are amenable for biomarker identification and drug-screening testing and led to the identification of the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer. | source |
| 3 | drug screening evidence | 2019 | Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. | Query term overlap: drug, screening, organoid, cancer; quality=2.48; cited_by=151; pmcid=PMC6562517 | The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines. | source |
| 4 | drug screening evidence | 2020 | Establishment of patient-derived cancer organoids for drug-screening applications. | Query term overlap: drug, screening, organoid, cancer, therapeutic; quality=2.47; cited_by=495 | The protocol provided may serve as a reference to successfully establish organoids from other cancer types and perform drug screenings thereof. | source |
| 5 | drug screening evidence | 2024 | Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids. | Query term overlap: drug, screening, organoid, cancer, therapeutic; quality=2.46; cited_by=82; pmcid=PMC10984622 | The anticancer activities of drug candidates were further validated in the established patient-derived organoids-based xenograft (PDOX) system in vivo. | source |
| 6 | drug screening evidence | 2018 | A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. | Query term overlap: drug, screening, organoid, cancer, therapeutic; quality=2.45; cited_by=556 | Here, we have established a primary gastric cancer organoid (GCO) biobank that comprises normal, dysplastic, cancer, and lymph node metastases (n = 63) from 34 patients, including detailed whole-exome and transcriptome analysis. | source |
| 7 | drug screening evidence | 2024 | Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. | Query term overlap: drug, screening, organoid, cancer, therapeutic; quality=2.42; cited_by=37; pmcid=PMC11293329 | Through RNA sequencing, the upregulation of tumor suppression genes/pathways is identified in 5-fluorouracil (FU)- or oxaliplatin-sensitive organoids, whereas genes/pathways associated with proliferation and invasion are enriched in chemotherapy-resistant organoids. | source |
| 8 | drug screening evidence | 2023 | Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application. | Query term overlap: drug, screening, organoid, cancer, therapeutic; quality=2.40; cited_by=27; pmcid=PMC10694672 | We have generated 61 BTC patient-derived organoids (PDOs) from 82 tumors (74.4%) that show similar histological and genetic characteristics to the corresponding primary BTC tissues. | source |
Initial Interpretation
The strongest current signal is drug screening evidence. The top-ranked source is Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. (2019). Manual verification is required before using this as a client-facing conclusion.
Evidence Gap Check
- Evidence is concentrated in one category: drug screening evidence. Add query variants to test for missing evidence types.
Action Plan
Verify
Open top sources and confirm title, abstract, date, and fit to the client question.
Refine
Add synonyms, comparator terms, and exclusion terms to reduce noise.
Deepen
Separate recent, foundational, and application-oriented evidence runs.
Deliver
Package a verified PDF, evidence table, and short recommendation memo.
Delivery Package
Visual Brief
Client-facing HTML/PDF-ready report with evidence dashboard and top sources.
Evidence Table
Ranked table with evidence label, support sentence, source link, and quality rationale.
Follow-up Plan
Clear next steps for deeper manual review, report expansion, or premium workflow.